1 – 80 of 80
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Eight Misconceptions about Prostate-Specific Antigen
(
- Contribution to journal › Article
- 2023
-
Mark
Pain as bad as you can imagine or extremely severe pain? A randomized controlled trial comparing two pain scale anchors
(
- Contribution to journal › Article
-
Mark
Predictive value of kallikrein forms and β-microseminoprotein in blood from patients with evidence of detectable levels of PSA after radical prostatectomy
(
- Contribution to journal › Article
- 2022
-
Mark
How Should Molecular Markers and Magnetic Resonance Imaging Be Used in the Early Detection of Prostate Cancer?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Predicting Grade group 2 or higher cancer at prostate biopsy by 4Kscore in blood and uCaP microRNA model in urine
(
- Contribution to journal › Article
-
Mark
Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence
(
- Contribution to journal › Article
- 2021
-
Mark
Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume
(
- Contribution to journal › Article
-
Mark
Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort
(
- Contribution to journal › Article
- 2020
-
Mark
Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years
(
- Contribution to journal › Article
-
Mark
Reply by Authors
(
- Contribution to journal › Article
-
Mark
A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy
(
- Contribution to journal › Article
-
Mark
The Four-Kallikrein Panel Is Effective in Identifying Aggressive Prostate Cancer in a Multiethnic Population
2020) In Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 29(7). p.1381-1388(
- Contribution to journal › Article
- 2019
-
Mark
Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re : Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961–7
(
- Contribution to journal › Letter
-
Mark
Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men
2019) In Prostate(
- Contribution to journal › Article
-
Mark
Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men
(
- Contribution to journal › Article
- 2018
-
Mark
Association Between Lead Time and Prostate Cancer Grade : Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening
(
- Contribution to journal › Article
-
Mark
Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men
(
- Contribution to journal › Article
- 2017
-
Mark
Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts
(
- Contribution to journal › Article
- 2016
-
Mark
Reply to Re : The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening
(
- Contribution to journal › Letter
-
Mark
The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening
(
- Contribution to journal › Article
-
Mark
Author Reply
(
- Contribution to journal › Letter
-
Mark
Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel
2016) In Journal of Urology(
- Contribution to journal › Article
-
Mark
Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice : A microsimulation screening analysis
(
- Contribution to journal › Article
- 2015
-
Mark
A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
2015) In European Urology(
- Contribution to journal › Article
-
Mark
Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
(
- Contribution to journal › Article
-
Mark
Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study.
(
- Contribution to journal › Article
- 2014
-
Mark
Cancer-associated Changes in the Expression of TMPRSS2-ERG, PCA3, and SPINK1 in Histologically Benign Tissue From Cancerous vs Noncancerous Prostatectomy Specimens.
(
- Contribution to journal › Article
-
Mark
The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men.
(
- Contribution to journal › Article
-
Mark
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
(
- Contribution to journal › Article
-
Mark
Inhibition of Circulating Dipeptidyl Peptidase 4 Activity in Patients with Metastatic Prostate Cancer
(
- Contribution to journal › Article
-
Mark
Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts : Results from the prostate biopsy collaborative group
(
- Contribution to journal › Article
- 2013
-
Mark
A Systematic Review of the Volume-Outcome Relationship for Radical Prostatectomy
(
- Contribution to journal › Scientific review
-
Mark
Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years.
(
- Contribution to journal › Article
-
Mark
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?
(
- Contribution to journal › Article
-
Mark
Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study
(
- Contribution to journal › Article
-
Mark
Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men : The PROBASE trial
(
- Contribution to journal › Article
- 2012
-
Mark
PSA is Dead, Long Live PSA
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Predicting prostate cancer many years before diagnosis : How and why?
(
- Contribution to journal › Article
-
Mark
We need a better marker for prostate cancer. How about renaming PSA?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Urological cancer : Time for another rethink on prostate cancer screening
(
- Contribution to journal › Article
-
Mark
Screening for Prostate Cancer: Early Detection or Overdetection?
(
- Contribution to journal › Scientific review
-
Mark
Prostate Cancer Screening: Facts, Statistics, and Interpretation in Response to the US Preventive Services Task Force Review
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses
(
- Contribution to journal › Article
-
Mark
Evaluation of Multiple Risk-Associated Single Nucleotide Polymorphisms Versus Prostate-Specific Antigen at Baseline to Predict Prostate Cancer in Unscreened Men
(
- Contribution to journal › Article
-
Mark
Levels of Beta-Microseminoprotein in Blood and Risk of Prostate Cancer in Multiple Populations.
2012) In Journal of the National Cancer Institute(
- Contribution to journal › Article
-
Mark
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators : Results from the prostate biopsy collaborative group
(
- Contribution to journal › Article
-
Mark
Evaluating the PCPT risk calculator in ten international biopsy cohorts : Results from the Prostate Biopsy Collaborative Group
(
- Contribution to journal › Article
- 2011
-
Mark
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection
(
- Contribution to journal › Article
-
Mark
Tumor markers in prostate cancer I: Blood-based markers
(
- Contribution to journal › Scientific review
-
Mark
Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
(
- Contribution to journal › Article
-
Mark
A Panel of Kallikrein Marker Predicts Prostate Cancer in a Large, Population-Based Cohort Followed for 15 Years without Screening
(
- Contribution to journal › Article
-
Mark
Prediction of Significant Prostate Cancer Diagnosed 20 to 30 Years Later With a Single Measure of Prostate-Specific Antigen at or Before Age 50
(
- Contribution to journal › Article
-
Mark
Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively
(
- Contribution to journal › Article
- 2010
-
Mark
Finasteride to prevent prostate cancer : Should all men or only a high-risk subgroup be treated?
(
- Contribution to journal › Article
-
Mark
Empirical Estimates of the Lead Time Distribution for Prostate Cancer Based on Two Independent Representative Cohorts of Men Not Subject to Prostate-Specific Antigen Screening.
2010) In Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology May 4. p.1201-1207(
- Contribution to journal › Article
-
Mark
Impact of Recent Screening on Predicting the Outcome of Prostate Cancer Biopsy in Men With Elevated Prostate-Specific Antigen Data From the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden
(
- Contribution to journal › Article
-
Mark
A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam
(
- Contribution to journal › Article
-
Mark
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer : Case-control study
(
- Contribution to journal › Article
-
Mark
Prostate Specific Antigen Velocity Does Not Aid Prostate Cancer Detection in Men With Prior Negative Biopsy
(
- Contribution to journal › Article
-
Mark
Blood Biomarker Levels to Aid Discovery of Cancer-Related Single-Nucleotide Polymorphisms: Kallikreins and Prostate Cancer.
(
- Contribution to journal › Article
-
Mark
Susceptibility Loci Associated with Prostate Cancer Progression and Mortality
(
- Contribution to journal › Article
-
Mark
The relationship between prostate-specific antigen and prostate cancer risk : The prostate biopsy collaborative group
(
- Contribution to journal › Article
- 2009
-
Mark
Prostate cancer : Estimating the benefits of PSA screening
(
- Contribution to journal › Article
-
Mark
Cutpoints in clinical chemistry : Time for fundamental reassessment
(
- Contribution to journal › Article
-
Mark
Systematic review of Pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer
(
- Contribution to journal › Article
-
Mark
THE CONTINUING ROLE OF PROSTATE-SPECIFIC ANTIGEN AS A MARKER FOR LOCALIZED PROSTATE CANCER: 'DO NOT THROW THE BABY OUT WITH THE BATH WATER'
(
- Contribution to journal › Article
-
Mark
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy
(
- Contribution to journal › Article
-
Mark
Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy
(
- Contribution to journal › Article
-
Mark
Prostate-Specific Antigen Velocity for Early Detection of Prostate Cancer: Result from a Large, Representative, Population-based Cohort
(
- Contribution to journal › Article
- 2008
-
Mark
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
(
- Contribution to journal › Scientific review
-
Mark
Systematic review of statistical methods used in molecular marker studies in cancer
(
- Contribution to journal › Article
-
Mark
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
(
- Contribution to journal › Article
-
Mark
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
(
- Contribution to journal › Article
-
Mark
Long-term prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population
(
- Contribution to journal › Article
-
Mark
Multi-institutional Study of Symptomatic Deep Venous Thrombosis and Pulmonary Embolism in Prostate Cancer Patients Undergoing Laparoscopic or Robot-Assisted Laparoscopic Radical Prostatectomy
(
- Contribution to journal › Article
- 2007
-
Mark
The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy
(
- Contribution to journal › Article
-
Mark
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
(
- Contribution to journal › Article
-
Mark
Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer
(
- Contribution to journal › Article
-
Mark
Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence
(
- Contribution to journal › Article
-
Mark
Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy
(
- Contribution to journal › Article